Claims for Patent: 9,028,833

Summary for Patent: 9,028,833

Title:	Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
Abstract:	The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
Inventor(s):	Govindan; Serengulam V. (Summit, NJ), Goldenberg; David M. (Mendham, NJ)
Assignee:	Immunomedics, Inc. (Morris Plains, NJ)
Application Number:	13/948,732
Patent Claims:	1. A method of treating colorectal, lung, stomach, urinary bladder, renal, breast, ovarian, uterine or prostatic cancer comprising administering to a human patient with colorectal, lung, stomach, urinary bladder, renal, breast, ovarian, uterine or prostatic cancer an immunoconjugate comprising SN-38 conjugated to an hRS7 (anti-TROP-2) antibody or antigen-binding fragment thereof; wherein the immunoconjugate is administered at a dosage of between 3 mg/kg and 18 mg/k, wherein the patient has failed to respond to at least one other therapy, prior to treatment with the immunoconjugate. 2. The method of claim 1, wherein the dosage is selected from the group consisting of 3 mg/kg, 4 mg/kg, 6 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 12 mg/kg, 16 mg/kg and 18 mg/kg. 3. The method of claim 1, wherein the treatment results in a reduction in tumor size of at least 15%, at least 20%, at least 30%, or at least 40%. 4. The method of claim 1, wherein the cancer is metastatic colon cancer and the patient has failed FOLFIRI chemotherapy prior to administration of the immunoconjugate. 5. The method of claim 1, wherein the cancer is triple-negative, metastatic breast cancer and the patient has failed therapy with CMF, carboplatin or paclitaxel prior to administration of the immunoconjugate. 6. The method of claim 1, wherein the cancer is metastatic lung cancer and the patient has failed therapy with carboplatin, bevacizumab, etoposide, topotecan, docetaxel or gemcitabine prior to administration of the immunoconjugate. 7. The method of claim 1, wherein the immunoconjugate comprises 4 or more molecules of SN-38 conjugated to the antibody or antigen-binding fragment thereof. 8. The method of claim 1, wherein the cancer is triple-negative breast cancer. 9. The method of claim 8, wherein the cancer is refractory to other therapies but responds to the immunoconjugate. 10. The method of claim 8, wherein the cancer is metastatic. 11. The method of claim 10, further comprising reducing in size or eliminating the metastases. 12. The method of claim 1, wherein there is a linker between the SN-38 and the antibody. 13. The method of claim 12, wherein the linker is CL2A and the structure of the immunoconjugate is MAb-CL2A-SN-38 ##STR00020## 14. The method of claim 13, wherein the 10-hydroxy position of SN-38 in MAb-CL2A-SN-38 is a 10-O-ester or 10-O-carbonate derivative using a `COR` moiety, wherein "CO" is carbonyl and the "R" group is selected from (i) an N,N-disubstituted aminoalkyl group "N(CH.sub.3).sub.2--(CH.sub.2).sub.n-" wherein n is 1-10 and wherein the terminal amino group is optionally in the form of a quaternary salt; (ii) an alkyl residue "CH.sub.3--(CH.sub.2).sub.n--" wherein n is 0-10; (iii) an alkoxy moiety "CH.sub.3--(CH.sub.2)n-O--" wherein n is 0-10; (iv) an "N(CH.sub.3).sub.2--(CH.sub.2).sub.n--O--" wherein n is 2-10; or (v) an "R.sub.1O--(CH.sub.2--CH.sub.2--O).sub.n--CH.sub.2--CH.sub.2--O--" wherein R.sub.1 is ethyl or methyl and n is an integer with values of 0-10. 15. The method of claim 1, wherein the immunoconjugate comprises 7 or less molecules of SN-38 conjugated to the antibody or antigen-binding fragment thereof. 16. The method of claim 1, wherein the immunoconjugate comprises 8 or less molecules of SN-38 conjugated to the antibody or antigen-binding fragment thereof. 17. The method of claim 1, wherein the immunoconjugate is administered at a dosage of between 8 mg/kg and 12 mg/kg. 18. The method of claim 1, wherein the immunoconjugate is administered at a dosage of between 8 mg/kg and 10 mg/kg. 19. A method of treating colorectal, lung, stomach, urinary bladder, renal, breast, ovarian, uterine or prostatic cancer comprising administering to a human patient with colorectal, lung, stomach, urinary bladder, renal, breast, ovarian, uterine or prostatic cancer an immunoconjugate comprising SN-38 conjugated to an hRS7 (anti-TROP-2) antibody or antigen-binding fragment thereof; wherein the immunoconjugate is administered at a dosage of between 3 mg/kg and 18 mg/kg, wherein the patient is resistant to or has relapsed from therapy with a camptothecin, prior to treatment with the immunoconjugate. 20. The method of claim 19, wherein the camptothecin is selected from the group consisting of irinotecan, topotecan and SN-38. 21. The method of claim 19, wherein the immunoconjugate is administered at a dosage of between 8 mg/kg and 12 mg/kg. 22. The method of claim 19, wherein the immunoconjugate is administered at a dosage of between 8 mg/kg and 10 mg/kg.

Details for Patent 9,028,833

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-12-13